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EDITORIAL
A role for T cell co-stimulation in ischemic acute renal failure?
Acute renal failure caused by ischemia is a common clinical
entity that is associated with significant morbidity and mortality
[1]. In kidney transplants, ischemic injury associated with procure-
ment and storage of the graft has a profound influence on events
following renal transplantation [2]. In the early post-transplant
period, severe allograft ischemia results in the syndrome of
delayed graft function. This syndrome has many clinical charac-
teristics of acute tubular necrosis but is also associated with an
increased incidence of acute rejection [3] and an increased risk for
chronic allograft failure [4]. Although the mechanisms connecting
ischemia to acute and chronic rejection are not clearly delineated,
ischemic injury produces enhanced expression of a series of
pro-inflammatory genes and upregulation of MHC antigen ex-
pression in the renal parenchyma [5]. These changes may enhance
the immunogenicity of the allograft and promote the influx and
activation of host lymphocytes. Such a synergistic relationship
between tissue injury and T lymphocyte activation has been
suggested to be a key element in the general regulation of immune
system functions [6].
Efforts to minimize ischemic injury associated with organ
harvesting and preservation have included meticulous donor
selection and management, the use of optimized preservation
solutions, and the minimizing of cold ischemia times. However,
pharmacological regimens instituted after harvesting and preser-
vation have often failed to prevent or ameliorate delayed graft
function. The paper by Chandraker and associates in this issue
of Kidney International [71 and another recent report published
by the same group [8] suggest an approach that may help
overcome this problem. These studies indicate that molecules
involved in T cell co-stimulation may play a key role in
ischemia-reperfusion injury in the kidney, independent of any
alloimmune stimulus. In a rat model of ischemia and reperfu-
sion, the authors show that administration of the recombinant
fusion protein CTLA4Ig completely prevents the acute rise in
serum creatinine immediately following ischemia-reperfusion
and significantly improves long-term survival of animals that
had been subjected to transient ischemia. CTLA4Ig treatment
also blocked the expression of pro-inflammatory cytokines and
reduced T cell and macrophage infiltration of the ischemic
kidney. Finally, treatment with CTLA4Ig prevented the devel-
opment of chronic proteinuria, a long-term sequela of ischemic
injury in this model, Thus, the administration of CTLA4Ig
dramatically ameliorated both the acute and chronic effects of
renal ischemia in this model.
CTLA4Ig was originally developed as an agent that would
inhibit or prevent T cell activation. The mechanism of action of
CTLA4Ig is conferred through its high affinity binding to B7-1
(CD8O) and B7-2 (CD86), two structurally-related glycoproteins
that are expressed on the surface of antigen presenting cells [9].
These proteins are the major ligands for CD28, a cell surface
receptor on T cells. The specific engagement of the T cell receptor
with the peptide-MHC protein complex delivers the first signal
leading to T cell activation. For productive T cell activation to
occur, a second signal is required that is delivered through
engagement of CD28 with the B7 ligands. When T cell receptor
engagement occurs without this "second signal," T cells are not
activated but rather are rendered anergic. Thus, CTLA4Ig, which
specifically blocks the interaction of CD28 and B7, provides a
potential approach for inducing donor-specific unresponsiveness.
In rodent models, treatment with CTLA4Ig improves allograft
survival and promotes immunological tolerance [10].
Aside from their role as activating ligands for CD28, no other
biological functions for B7 proteins have been identified. B7-1 and
B7-2 are expressed on specialized antigen presenting cells and
their expression can be up-regulated in other tissues during the
course of immune responses such as allograft rejection [9].
Ischemic insult appears to cause such an increase B7 expression in
the kidney [8]. The experiments of Chandraker et al suggest that
B7-2 may have unique effects in promoting ischemic injury. While
the details of these effects are unclear, previous studies have also
identified distinct functions for B7-2 related to T cell activation.
For example, B7-2 induces naive T cells to produce IL-4 and thus
may promote a TH2 response, while B7-1 induces a more neutral
cytokine response [11].
Although previous work has demonstrated the importance of
non-specific inflammatory pathways in the pathogenesis of isch-
emic acute renal failure [12], a role for antigen-specific T cell
responses had not been suspected. Chandraker and associates
now provide compelling evidence that the CD28:B7 co-stimula-
tion pathway contributes to ischemia-reperfusion injury. Whether
the detrimental effects mediated by B7-2 and the protection
conferred by CTLA4Ig in ischemia are related to activation of T
cells or to some other as yet unidentified function remains to be
determined. Failure of other anti-T cell therapies to ameliorate
ischemic renal failure and the ability of CTLA4Ig to prevent early
events within 24 hours after injury would suggest that the effects
of B7-2 to promote ischemic injury may not involve specific T cell
activation. The authors do advance the hypothesis that ischemia
may lead to the uncovering or expression of neo-antigens that, in
the context of a dramatic upregulation of MHC class II expres-
sion, may serve as the focus of a specific T cell response. However,
the kinetics of this cellular immune process are unexplained.
Whether or not T cells are found to have a direct role in ischemic
acute renal failure, the discovery of these novel effects of the
CD28:B7 pathway in a rat model of this disorder suggests a
rationale for new treatment strategies.
Whether such strategies are applicable to humans is not certain.
To date, most of the data defining the therapeutic potential of
CTLA4Ig come from rodent models. Whether this agent will have
similar efficacy in humans should become clear as clinical trials
with human CTLA4Ig move forward. In primate transplant
models, CTLA4Ig has performed well in combination with other
anti-T cell therapies [13]. A potential dual efficacy in reducing the
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likelihood of both ischemic injury and rejection would be uniquely
attractive in the clinical setting. This clinical utility would be
further expanded if CTLA4Ig is found to be beneficial in other
situations associated with tissue injury due to ischemia.
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